AMX0035 Prolonged Time to Ventilation, Tracheostomy in CENTAUR Trial
Treatment with AMX0035 significantly prolonged the time that people with amyotrophic lateral sclerosis (ALS) in the CENTAUR clinical…
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Treatment with AMX0035 significantly prolonged the time that people with amyotrophic lateral sclerosis (ALS) in the CENTAUR clinical…
Team Gleason and Synchron have entered into a partnership aiming to advance a technology that offers greater accessibility…
ProMIS Neurosciences announced plans to advance a monoclonal antibody against toxic TDP-43 protein clumps as a potential treatment for amyotrophic lateral…
Treatment with AMX0035 significantly extended the median survival of amyotrophic lateral sclerosis (ALS) patients by more than 10 months compared…
WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS)Â associated with mutations in the C9ORF72…
Treatment with Coya Therapeutics‘ ALS001, a regulatory T-cell (Treg) therapy being developed for amyotrophic lateral sclerosis (ALS), was found…
“Clustering” people with amyotrophic lateral sclerosis (ALS) based on biological data could be useful for identifying those most likely…
The experimental therapy WVE-004 appears to be engaging its intended target and reducing the amount of toxic proteins in people…
A CRISPR-based gene editing system could be used to reduce the activity of genes associated with amyotrophic lateral sclerosis…
A novel system that involves electrodes implanted in the brain allowed a 34-year-old man with amyotrophic lateral sclerosis (ALS)…